Regulatory strategy and intelligence for registration, evidence, manufacturing compliance and lifecycle management across the Eurasian Economic Union.
Regional framework, national execution
EAEU programmes combine Union-level rules with execution in the selected reference and recognition states. Pharegis supports dossier strategy, quality, GMP, evidence, product information, pharmacovigilance and lifecycle work across that interface.
EAEU technical guidance
- Drug Registration in Russia under EAEU Rules: Dossier Strategy, Quality Expertise and Market Authorization
- EAEU Dossier Alignment after 31 December 2025: Transitional Cases and Portfolio Decisions
- EAEU Variations Management: Classification, Grouping and Lifecycle Control
- EAEU Quality Document and Pharmacopoeial Alignment
- EAEU SmPC, Patient Leaflet and Labeling: Harmonizing Product Information Across Member States
- EAEU GMP Inspection and Certification for Foreign Pharmaceutical Manufacturers
- When EAEU Registration Requires Clinical or Bioequivalence Evidence
- Local Clinical Studies in Russia: Protocol Development, Ministry Approval and Vendor Strategy
- Using Foreign Clinical Studies for EAEU Registration: When a GCP Inspection Can Replace a New Local Trial
- Can My Drug Use a BCS Biowaiver Instead of an EAEU Bioequivalence Study?
- Preclinical Evidence for EAEU Registration: Module 4, GLP and When New Studies Are Actually Needed
- Preclinical Studies for Biological and Biosimilar Medicinal Products in the EAEU
- EAEU Pharmacovigilance: Marketing Authorization Holder, Vendor Selection and Sponsor Oversight
- Medical Device Registration in Russia and the EAEU: Pathway, Evidence, QMS and Clinical Strategy
- Regulatory Consulting for EAEU Market Entry and Lifecycle